Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Constellium: very strong Q4 2025 results with the momentum continuing into H1 2026|Eramet publishes weak results for 2025 but takes radical measures to rapidly improve its financial structure, notably with a plan to strengthen its equity capital by € 500m|AF-KLM: Unit costs under control enabling good profitability levels|
Constellium: very strong Q4 2025 results with the momentum continuing into H1 2026|Eramet publie de faibles résultats 2025 mais prend des mesures radicales pour améliorer rapidement la structure financière, notamment avec un projet de renforcement des fonds propres de 500 m EUR|AF-KLM: Unit costs under control enabling good profitability levels|
Rdos. 4T'25 vs 4T'24: Ventas: 25.984 M euros (+5,1% vs +6,6% BS(e) y +7,3% consenso); EBIT: 2.982 M euros (+16,7% vs +8,6% BS(e) y +12,1% consenso); BDI: 2.304 M euros (+24,3% vs +3,6% BS(e) y +7,4% consenso). Rdos. 2025 vs 2024: Ventas: 73.420 M euros (+6,1% vs +6,6% BS(e) y +6,8% consenso); EBIT: 7.128 M euros (+33,1% vs +29,3% BS(e) y +30,9% consenso); BDI: 4.996 M euros (+25,2% vs +15,6% BS(e) y +17,3% consenso).
Rdos. 2T'26 vs 2T'25: Ventas: 2.869 M euros (-15,4% vs -12,5% BS(e) y -15,2% consenso). Rdos. 1S'26 vs 1S'25: Ventas: 5.253 M euros (-14,9% vs -13,3% BS(e) y -14,8% consenso); EBIT: 1.614 M euros (-18,7% vs -19,0% BS(e) y -21,4% consenso); BDI: 975,0 M euros (-18,1% vs -15,1% BS(e) y -17,6% consenso).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.